ClinicalTrials.gg

Program

Bosentan

Also written as “bosentan”, “Bosentan 125 mg” and “Bosentan 62.5 mg”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Idiopathic Pulmonary Fibrosis · digital ulcers · Scleroderma, Systemic, led by 5 companies.

Furthest: phase 4, since Apr 30, 200430 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson260 open or runningphase 4since Apr 30, 2004Oct 6, 2003none ahead
Geropharm10 open or runningphase 1since Sep 23, 2019Sep 23, 2019none ahead
Hanmi Pharmaceutical10 open or runningphase 1since May 20, 2013May 20, 2013none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Jun 26, 2024Jun 26, 2024none ahead
Retinset SL10 open or runningphase 1since Aug 22, 2019Aug 22, 2019none ahead

Also a collaborator on its studies: Dong-A ST.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since Oct 6, 2003.

  1. Aug 21, 2006Phase 4 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT00367770 · 37 enrolled · United States, Australia, Austria and more
  2. Oct 20, 2006Phase 3 study in Idiopathic Pulmonary FibrosisJohnson & Johnson · NCT00391443 · 616 enrolled
  3. Feb 7, 2007Phase 4 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT00433329 · 100 enrolled
  4. Jan 7, 2008Phase 4 study in Hypertension, PulmonaryJohnson & Johnson · NCT00595049 · 11 enrolled · Australia
  5. Feb 12, 2008Phase 3 study in Idiopathic Pulmonary FibrosisJohnson & Johnson · NCT00631475 · 128 enrolled
  6. Oct 14, 2009Phase 2 study in MelanomaJohnson & Johnson · NCT01009177 · 80 enrolled · Australia
  7. Oct 12, 2010Phase 3 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT01223352 · 64 enrolled
  8. Apr 15, 2011Phase 3 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT01338415 · 58 enrolled · United States, Australia, Belarus and more
  9. Jun 30, 2011Phase 3 study in Persistent Fetal Circulation SyndromeJohnson & Johnson · NCT01389856 · 23 enrolled
  10. Jul 6, 2011Phase 4 study in Scleroderma, SystemicJohnson & Johnson · NCT01395732 · 18 enrolled · Netherlands
  11. May 20, 2013Hanmi Pharmaceutical's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01864863 · 28 enrolled · Korea, Republic of
  12. Aug 22, 2019Retinset SL's first study: phase 1 study in Diabetes MellitusNew to Retinset SLRetinset SL · NCT04068272 · 22 enrolled · Spain
  13. Sep 23, 2019Geropharm's first study: phase 1 study in FastingNew to GeropharmGeropharm · NCT04101370 · 64 enrolled · Russian Federation
  14. Jun 26, 2024Humanis Saglık Anonim Sirketi's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06484673 · 32 enrolled · Jordan

TargetBeta

EDNRA →EDNRB →read by rule
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
aprocitentanruleIdorsia Pharmaceuticalsphase 314

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06484673Pulmonary Arterial Hypertension · Jordan1CompletedHumanis Saglık Anonim SirketiMay 22, 202432
NCT04101370Fasting · Russian Federation1CompletedGeropharmJun 20, 201864
NCT04068272Diabetes Mellitus · Spain1CompletedRetinset SLMay 20, 202222
NCT01864863Pulmonary Arterial Hypertension · Korea, Republic of1CompletedHanmi PharmaceuticalMay 201328
NCT01395732Scleroderma, Systemic · Netherlands4CompletedJohnson & JohnsonNov 30, 201218
NCT01389856Persistent Fetal Circulation Syndrome3TerminatedJohnson & JohnsonDec 201323
NCT01338415Pulmonary Arterial Hypertension · United States, Australia, Belarus and more3CompletedJohnson & JohnsonAug 13, 201458
NCT01223352Pulmonary Arterial Hypertension3CompletedJohnson & JohnsonApr 3, 201364
NCT01009177Melanoma · Australia2CompletedJohnson & JohnsonFeb 29, 200880
NCT00631475Idiopathic Pulmonary Fibrosis3CompletedJohnson & JohnsonApr 2010128
NCT00595049Hypertension, Pulmonary · Australia4CompletedJohnson & JohnsonDec 31, 200811
NCT00433329Pulmonary Arterial Hypertension4CompletedJohnson & JohnsonMay 2010100
NCT00391443Idiopathic Pulmonary Fibrosis3CompletedJohnson & JohnsonFeb 2010616
NCT00367770Pulmonary Arterial Hypertension · United States, Australia, Austria and more4CompletedJohnson & JohnsonDec 200537
NCT00360087Hypertension, Pulmonary3TerminatedJohnson & JohnsonAug 2007236
NCT00319696digital ulcers3CompletedJohnson & JohnsonJan 22, 2009116
NCT00319267Pulmonary Arterial Hypertension3CompletedJohnson & JohnsonDec 200636
NCT00319111Hypertension, Pulmonary3CompletedJohnson & JohnsonFeb 2009151
NCT00319033Lung Diseases, Interstitial3CompletedJohnson & JohnsonFeb 2006132
NCT00319020Pulmonary Arterial Hypertension3CompletedJohnson & JohnsonOct 28, 201133
NCT00317486Pulmonary Arterial Hypertension4CompletedJohnson & JohnsonApr 200554
NCT00313222Chronic Thromboembolic Pulmonary Hypertension3CompletedJohnson & JohnsonFeb 2007157
NCT00313196Hypertension, Pulmonary3TerminatedJohnson & JohnsonAug 200712
NCT00310830Hypertension, Pulmonary3TerminatedJohnson & JohnsonAug 200714
NCT00303459Pulmonary Arterial Hypertension4CompletedJohnson & JohnsonDec 2013334
NCT00091715Hypertension, Pulmonary · United States, Australia, Austria and more3CompletedJohnson & JohnsonNov 2006185
NCT00082186Hypertension, Pulmonary4CompletedJohnson & JohnsonFeb 200722
NCT00077584digital ulcers3CompletedJohnson & JohnsonMar 2005188
NCT00071461Idiopathic Pulmonary Fibrosis · United States, Canada, France and more3CompletedJohnson & JohnsonSep 2005158
NCT00070590Pulmonary Fibrosis3CompletedJohnson & JohnsonSep 2005132

How it is read

Names in the registry

  • “Bosentan”, 19 entries
  • “bosentan”, 12 entries
  • “Bosentan 125 mg”, 3 entries
  • “Bosentan 62.5 mg”, 2 entries
  • “Bosentan Dispersible Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.